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Acute lung injury (ALI) frequently occurs in traumatic patients and serves as an important component of systemic inﬂammatory
response syndrome (SIRS). Hemorrhagic shock (HS) that results from major trauma promotes the development of SIRS and
ALI by priming the innate immune system for an exaggerated inﬂammatory response. Recent studies have reported that the
mechanism underlying the priming of pulmonary inﬂammation involves the complicated cross-talk between Toll-like receptors
(TLRs)andinteractionsbetween neutrophils(PMNs)andalveolar macrophages(AMφ)aswellasendothelialcells(ECs),inwhich
reactive oxygen species (ROS) are the key mediator. This paper summarizes some novel mechanisms underlying HS-primed lung
inﬂammation focusing on the role of TLRs and ROS, and therefore suggests a new therapeutic target for posttrauma ALI.
1.Introduction
Trauma is the ﬁfth leading cause of death among all age
groups in the United States and is the leading cause of death
among people less than 45 years of age [1]. Hemorrhagic
shock (HS) that results from major trauma promotes the
development of systemic inﬂammatory response syndrome
(SIRS) by priming the innate immune system for an exagger-
ated inﬂammatory response [2]. The lung is an important
target organ for systemic inﬂammatory mediators released
after severe infection [3, 4]a n dt r a u m a[ 5–7], and thus acute
lunginjury(ALI)frequentlyoccursintraumaticpatientsand
serves as an important component of SIRS [8]. Over the
past decade, despite improvements in supportive care, ALI is
still associated with a high mortality rate ranging from 26 to
35 percent [9]. Resuscitated HS promotes the development
of ALI by priming an ampliﬁed inﬂammatory response to
a second stimulus, the so-called “two-hit hypothesis” [10].
However, the mechanism underlying HS-primed inﬂamma-
tion has yet to be fully determined.
Morphologically, ALI is manifested by alveolar and
interstitial ﬂuid accumulation, alveolar hemorrhage, ﬁbrin
deposition, and lung neutrophil sequestration. The accu-
mulation of neutrophils (PMNs) in the lung vasculature,
interstitium, and alveolar space is considered a critical event
and has been the target of various preventative strategies. In
our laboratory, a simpliﬁed animal model of the “two-hit”
paradigm, as an example of human diseases, has been used
to address the mechanisms of HS-primed PMNs migration
and lung inﬂammation [4]. In this model, animals are
subjected to a nonsevere resuscitated HS (hypotension at
40mmHg for 1h), followed by a small intratracheal dose
of lipopolysaccharides (LPSs). While neither shock nor LPS
alone induced injury, the combination caused lung PMNs
accumulation and increased 125I-albumin transpulmonary
ﬂux [11], suggesting that the mechanisms underlying the
HS-primed ALI involve cross talk between Toll-like recep-
tors (TLRs) and interactions between PMNs and alveolar
macrophages (AMφ) as well as endothelial cells (ECs), in
whichreactiveoxygenspecies(ROSs)areakeymediator.The2 Mediators of Inﬂammation
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Figure 1: Role of TLRs in mediating inﬂammation and organ
injury. Infection not only causes PAMPs release, but also causes
tissue and cell damage along with subsequent DAMPs release.
Similarly, injury caused by trauma or various other factors not only
leadstoDAMPsreleasebutalsorendersthepatientmoresusceptible
to infection and therefore PAMPs release. In turn, PAMPs and
DAMPs act through TLRs to activate the innate immune system,
yet they can also contribute to persistent and deleterious systemic
inﬂammation and organ injury, including ALI.
purpose of this paper is to summarize some novel mech-
anisms underlying HS-primed lung inﬂammation focusing
on the role of TLRs and ROS, and therefore suggest a new
therapeutic target for post-trauma ALI.
2 .T h eR o l eo fT L R sinA L I
Toll-like receptors (TLRs) are the ﬁrst family of pattern
recognition receptors (PRRs) discovered in mammals. It is
now well accepted that in addition to recognizing pathogen-
associated molecular pattern molecules (PAMPs), TLRs
can also respond to endogenous molecules released in
response to stress, trauma, and cell damage. These molecules
have been termed damage-associated molecular patterns
(DAMPs) [12]. Interaction between PAMPs and DAMPs
enhances the inﬂammatory response through TLR signaling,
as illustrated in Figure 1.
Activation of TLRs initiates two major pathways: the
MyD88-dependentpathway,whichisusedbyallTLRsexcept
TLR3, resulting in the activation of NF-κBa n da c t i v a t o r
protein-1 (AP-1); and the TRIF-dependent pathway, which
is initiated by TLR3 and TLR4, resulting in the activation
of type I interferons (IFNs) [13–15]. TLRs are expressed
on a range of immune cells including PMNs, macrophages,
dendritic cells (DCs), B cells, and certain types of T cells, as
well as on certain nonimmune cells, such as endothelial cells,
smooth muscle cells, and epithelial cells that lie at potential
sites of entry, including the skin, respiratory tract, intestinal
tract, and genitourinary tracts [16, 17].
TLR4 and TLR2 sit at the interface of microbial and ster-
ile inﬂammation by selectively responding to both bacterial
products and endogenous ligands [18], including hyaluronic
acid [19], heparan sulfate [20], ﬁbrinogen [21], heat shock
proteins [22], and high-mobility group box 1 (HMGB1)
[23, 24]. Both inﬂammation and injury responses in organs
subjected to ischemia/reperfusion depend, at least partially,
on TLR4 and TLR2 [23–26]. Previous studies from both
our group and others have demonstrated that a low level
expression of TLR2 in cells can be upregulated by TLR4 sig-
naling [27, 28], suggesting a mechanism of inducible cellular
sensitivitytobothexogenousandendogenousstimuli.Inthis
paper, we will focus on the role of TLR4 and TLR2 cross talk
in the mechanisms of post-trauma ALI.
2.1. Role of TLR4. Expression of functional TLR4 has been
found in many cell types in the lung [29]. LPS-induced lethal
shock and ALI are TLR4 dependent [30–32]. Findings from
our laboratory have demonstrated that LPS downregulates
TLR4 expression in AMφ, whereas antecedent HS prevents
the decrease in TLR4 gene transcription in response to LPS;
also, LPS-induced TLR4 mRNA destabilization is reduced in
theAMφ exposedtoHSascomparedtothatinshamanimals
[33]. These ﬁndings suggest that sustained TLR4 expression
following HS may contribute to an enhanced cell response to
LPS [33].
Recent studies have shown that HMGB1 is a potent
activator of TLR4 [34]. The activation of TLR4 signaling
by HMGB1 has been veriﬁed in cell lines [35, 36]. HMGB1
was initially identiﬁed as a nuclear protein that stabilized
nucleosome formation and acted as a transcription factor
regulating the expression of several genes [37]. HMGB1 is
now known to be as an early inﬂammatory mediator in
ischemia [23, 24], trauma, HS, and noninfectious hepatitis
[38, 39]. Marked increase in HMGB1 levels in serum,
lungs, and liver was detected within 2h after HS in mice
[40]. Regarding how HS induces HMGB1 secretion, study
has shown that epinephrine directly acts through Mφβ -
adrenergic receptor to stimulate HMGB1 secretion from the
Mφ in an autocrine manner [41].
2.2. Role of TLR2. TLR2 is predominantly expressed in the
cells involved in ﬁrst-line host defense, including monocytes,
macrophages, dendritic cells, and PMNs [27, 42]. In ECs and
epithelial cells the TLR2 expression is low [27], but can be
upregulated [43]. TLR2 senses a broad range of components
from bacteria, mycoplasma, fungi, and viruses. These com-
ponents include lipoproteins from a number of pathogens,
PGN and LTA from Gram-positive bacteria, LAM from
mycobacterium, glycosylphophatidylinositol anchors from
Trypanosoma Cruzi, a phenol-soluble modulin from Staphy-
lococcusepidermis,zymosanfromfungi,andglycolipidsfrom
Treponema maltophilum [44–47].TLR2recognizesitsligands
by forming a heterodimer with either TLR1 or TLR6. The
resulting TLR1/TLR2 and TLR6/TLR2 complexes recognize
distinct ligands, triacyl and diacyl lipoproteins, respectively.
We have reported that in HS, HMGB1 through TLR4
signaling upregulates TLR2 in ECs, and this upregulationMediators of Inﬂammation 3
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Figure 2: Model of shock-activated PMN in mediating the TLR4-TLR2 cross talk in AMφ and AMφ priming. Hemorrhagic shock-
activated PMNs primarily migrate into alveoli in response to a trivial inﬂammatory stimulus, such as LPS, and interact with AMφ.T h e
interaction between PMN and AMφ enhances LPS-induced TLR2 expression (+) in the AMφ, possibly mediated by PMNs-derived oxidants
and augmented NF-κB activation. The increased TLR2 expression results in the ampliﬁed response of AMφ to the TLR2 agonist (PGN),
thereby augmenting cytokines and chemokines expression (circled +) and promoting enhanced PMN transalveolar migration. Thus, the
shock-activated PMN-mediated TLR4-TLR2 cross talk activates a positive feedback signal leading to AMφ priming and exaggerated lung
inﬂammation in response to invading pathogens.
associates with an ampliﬁed EC function including aug-
mented activation of NADPH oxidase and expression of
ICAM-1 in response to TLR2 activation by HMGB1 [48].
Previous reports, using both in vivo HS mouse model
and in vitro PMN-AMφ coculture approaches, have also
demonstrated that TLR4 upregulates TLR2 expression in
AMφ, and this upregulation is signiﬁcantly augmented
by HS-activated PMNs [49]. The ampliﬁed TLR4-induced
TLR2 expression in AMφ serves as an important mechanism
underlying HS-primed lung inﬂammation in response to
a second challenge from bacterial products. The study
shows that upregulated TLR2 markedly increases expression
of macrophage inﬂammatory protein-2 (MIP-2), cytokine
migration inhibitory factor (MIF), and TNF-α in the AMφ
andinducesaugmentedPMNmigrationinresponsetoTLR2
ligand PGN (Figure 2)[ 49].
The inducible expression of TLR2 suggests an important
physiological signiﬁcance of TLR-TLR cooperativity, namely
that as ligand activation of TLR4 signaling wanes, the
signaling functions can be transferred to TLR2, and thus the
TLR mediated cellular response can be maintained over a
p r o l o n g e dp e r i o do ft i m e[ 28, 50].
3. The Role of ROS inALI
ROS is a collective term that includes a large variety of free
oxygen radicals, for example, superoxide anion (O2
￿−)a n d
hydroxyl radicals (
￿OH), as well as derivatives of oxygen
that do not contain unpaired electrons, such as hydrogen
peroxide (H2O2), hypochlorous acid (HOCl), peroxynitrite
(ONOO), and ozone (O3)[ 51]. During normal cellular
metabolism, ROS are steadily produced. However, recent
reports have demonstrated their involvement in signaling
which aﬀects cellular functions including gene expression,
proliferation, cell death, migration, and inﬂammation [52].
ROS are generated from various catalytic pathways mediated
by enzymes which are diﬀerentially localized inside the cell,
including NO synthases, enzymes of the respiratory chain,
cytochrome P450 monoxygenases, xanthine oxidase, and
NADPH oxidase.
Studies have suggested that ischemia/reperfusion primes
circulating PMNs for increased ROS production, thereby
augmenting PMN-mediated lung injury once the PMNs are
sequestered in the lung [53, 54]. ROS appear to participate
in the regulation of TLR4 gene expression. The use of
the antioxidant N-acetylcysteine (NAC) supplementation
duringresuscitationmarkedlyreducedlevelsofTLR4mRNA
and partially reverses the prolongation of TLR4 mRNA half-
life observed following HS [33].
3.1. NADPH Oxidase is an Important Source of ROS in
HS. Emerging evidence has shown that ROS derived from
NADPH oxidase play an important role in mediating organ
injury after HS [55–57]. The NADPH oxidase complex4 Mediators of Inﬂammation
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Figure 3: Model of HS-induced PMN NADPH oxidase activation.
HMGB1 acts through TLR4 and MyD88-dependent signaling to
mediate HS-induced NADPH oxidase activation. Akt and P38 MAP
kinase are both involved in this event.
presents in a variety of phagocytic and nonphagocytic cells.
The phagocytic NADPH oxidase serves a critical function in
host defense against invading microorganisms. However, the
nonphagocytic NADPH oxidase has been thought to mainly
induce oxidant signaling, although oxidant generation is
markedlylessinnonphagocyticcells[58].NADPHoxidaseis
a group of multimeric enzymes whose activity results in the
production of O2
−. NADPH oxidase consists of 5 subunits:
p40phox,p 4 7 phox, p67phox,p 2 2 phox,a n dg p 9 1 phox. In the basal
state, p40phox,p 4 7 phox, and p67phox exist in the cytosol as
a complex, while p22phox and gp91phox are located in the
membranes of secretory vesicles and speciﬁc granules of
PMN, where they aggregate to form a heterodimeric ﬂavo-
hemoprotein known as cytochrome b558. Upon stimulation,
the cytosolic component p47phox is phosphorylated and the
entire cytosolic complex migrates to the membrane where
it associates with cytochrome b558 to assemble the active
oxidase [58]. Although all of the ROS-producing enzymes
contribute to the oxidative burden, NADPH oxidase seems
to be a key source of ROS, and evidence has shown that an
initial generation of ROS by NADPH oxidase triggers the
release of ROS by other enzymes [59].
It has been demonstrated that HS through HMGB1
activates the TLR4-MyD88-IRAK4 signaling pathway and
further activates p38 MAPK and Akt pathways to initiate
phosphorylation of p47phox and subsequent activation of
NADPH oxidase (Figure 3)[ 2]. The ROS derived from
PMN NADPH oxidase not only play an important role in
enhancing TLR2 upregulation in AMφ and ECs, as described
below, but also contribute to endothelial NADPH oxidase
activationinHS[48].Thestudyshowsthatoxidantsignaling
by the PMN NADPH oxidase enhances the activation of EC
NADPH oxidase in response to HS through a signaling path-
way involving HMGB1, TLR4, and Rac1, but independent of
p38 MAPK [48].
3.2. Role of ROS in TLR2 Upregulation in AMφ. We have
reported an important role of PMN NADPH oxidase in
mediating ampliﬁed LPS-induced TLR2 upregulation in
AMφ [40]. Using both in vivo hemorrhage mouse model
and in vitro PMN-AMφ coculture approaches, the studies
demonstrated that the TLR4-dependent TLR2 upregulation
in AMφ is signiﬁcantly augmented by antecedent shock; and
thiseﬀectofshockisparticularlymediatedbyshock-induced
ROS released from PMN. The endogenous NADPH oxidase
in AMφ may also be involved in the signal transduction,
however, the exogenous ROS from PMN NADPH oxidase
are essential for inducing ampliﬁed TLR2 expression in AMφ
in response to TLR4 signaling, because when the AMφ from
NADPH oxidase-deﬁcient gp91phox−/− mice were cocultured
with PMNs isolated from WT mice subjected to shock, the
expression of TLR2 in the gp91phox−/− AMφ was elevated to
the same level as that in WT AMφ [40]. Figure 3 illustrates
the physiological signiﬁcance of the ROS-augmented TLR2
upregulation by TLR4 in AMφ.
3.3. Role of ROS in TLR2 Upregulation in Lung EC. ROS also
contribute to LPS/TLR4 signaling induced TLR2 expression
in lung EC [28]. LPS through TLR4-MyD88-dependent
signaling activated NF-κB and induced TLR2 expression
in ECs, and this process was enhanced by oxidant signal-
ing generated by PMN NADPH oxidase. The functional
relevance of NADPH oxidase in mediating TLR4-induced
TLR2 expression in ECs was evident by markedly elevated
and stable ICAM-1 expression as well as augmented PMN
migration in response to sequential challenge with LPS and
PGN (Figure 4)[ 28].
Interaction of PMNs with ECs is important for the
process of PMN sequestration into the lung [30, 60]. EC
activation and expression of adhesion molecules are critical
to initiate a ﬁrm ICAM-1-dependent PMN adhesion to EC
and, thus, mediate the early-onset migration of PMNs across
the endothelial barrier. In vivo PMN depletion and repletion
experiments demonstrated that PMN NADPH oxidase is an
important determinant of TNFα-induced NF-κBa c t i v a t i o n
and ICAM-1 expression in lung EC [61]. In vitro PMN-EC
coculture study also showed that WT PMNs induced a rapid
and augmented increase in ICAM-1 expression in lung ECs
from WT and NADPH oxidase-deﬁcient p47phox−/− mice
in response to TNFα stimulation; while, antioxidant GSH
prevented the eﬀect of WT PMNs in amplifying ICAM-1
expressionintheECs,indicatingthattheinteractionbetween
PMNsand ECs is mediated throughPMN-derived ROS[62].
4.TargetingBoth TLRsandROSasaNovel
TherapeuticStrategyforALI
As described above, ROS derived from PMN NADPH
oxidase through interaction between PMNs and AMφ or
PMNs and lung ECs mediate an augmented upregulation
of TLR2 in the AMφ and ECs following HS, and in turn,
sensitize the cells to TLR2 agonists, exaggerate inﬂammatory
response, and promote the development of ALI. Based onMediators of Inﬂammation 5
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these ﬁndings, targeting both TLRs and ROS simultaneously
may present a novel therapeutic strategy for ALI.
Drugs targeting TLRs mainly include either agonists of
TLRs to enhance immune responses against infectious agent,
orantagonistsdesignedtoreduceinﬂammationduetoinfec-
tion or autoimmune responses [63]. Since TLR4 deﬁciency
displayed a beneﬁcial eﬀect in attenuating inﬂammation
following trauma, HS, and ischemia/reperfusion [23, 48,
64, 65], TLR antagonists should be considered during the
treatment of post-trauma ALI. The approaches to reduce
TLR activity have focused on two aspects: (a) monoclonal
antibodies, soluble receptors, and other accessory proteins
and (b) signal transduction blockers. For instance, a natural
soluble form of TLR2 has been found in mouse plasma and
breast milk that acts to block TLR2 ligand stimulation [66].
In addition, a member of the TLR/IL-1 receptor family, TIR8
or SIGIRR, has been described to inhibit NF-κB signaling
and suggested an endogenous inhibitor of the TLR system
[67].Manyofthekeymoleculesinthesignalingpathwaysfor
each TLR have been identiﬁed and are considered druggable
targets [43, 68, 69]. The structural basis of the TIR domain
of TLRs and adapters, such as MyD88, Mal, TRAM, or TRIF,
hasbeenmodeled,andsmallpeptidicsequencesbasedonthe
T I Rd o m a i nB Bl o o po rp e p t i d o m i m e t i c so ft h i sr e g i o nh a v e
been made that can block the interactions [69–71]. Although
the drugs targeting TLRs have not yet been applied to the
treatmentofALI,thecriticalroleofTLRsinthedevelopment
of ALI targeting of PRRs has opened up a productive area for
the therapy of ALI.
ROS-induced injury was considered to occur by at
least two major mechanisms: (a) a direct toxic eﬀect of
reactive oxygen species on cellular components including
lipid peroxidation, oxidation of critical protein thiols on
enzymes, and structural protein and nucleic acid damage
[72]; (b) an indirect eﬀect mediated via activation of
cell signaling pathways culminating in the generation of a
number of proinﬂammatory molecules [73]. The role of
ROS in augmenting TLRs crosstalk is now a new addition
to the mechanisms underlying ROS-induced organ injury.
Moreover, ROS overwhelm the endogenous antioxidant
mechanisms, thereby rendering tissues more susceptible to
oxidant damage. Indeed, excessive oxidative stress has been
shown to correlate with poor outcomes in patients with
acute respiratory distress syndrome [74, 75]. Therefore, one
potential strategy for obviating the eﬀects of oxidative stress
is to employ antioxidant strategies aimed at neutralizing
oxidants or enhancing endogenous antioxidant mechanisms.
NAC combines both of these properties. NAC can exert
antioxidant activity through a direct scavenger eﬀect by
virtueofitsreducedsulfhydrylgroupandalsobyenteringthe
cell and releasing cysteine, which contributes to the synthesis
of intracellular reduced glutathione, an important regulator6 Mediators of Inﬂammation
of the intracellular redox balance [76]. This drug is also
attractive for use in humans, since there is long-standing
experiencewithitsuseinthemanagementofacetaminophen
toxicity [77]. In fact, some human studies including those
employing NAC as the antioxidant have shown antioxidant
therapy to be beneﬁcial [78–81]. Eﬀective NADPH oxidase
inhibitors also have been investigated in the attempt to
salvage organs from oxidative injury. Two chemically dis-
tinct inhibitors of NADPH oxidase, namely diphenylene
iodonium (DPI) and 4-hydroxy-3-methoxy-acetophenone
(apocynin), have been found to reduce the organ injury
associated with HS [55]. Apocynin in combination with
TNF-α converting enzyme inhibitor (TACEI) can completely
prevent lung from ischemic injury [61]. This system may
represent an eﬀective therapeutic approach for the delivery
of antioxidants and other anti-inﬂammatory treatments into
the lung after HS.
5. Conclusion
The current pharmacotherapy has not been highly suc-
cessful in increasing survival during ALI. The role of TLR
signaling in the development of ALI has now been well
recognized. Recent studies have further demonstrated that
ROS are important determinants for augmented TLR4-
induced TLR2 upregulation in HS. Therefore, antioxidant
strategies together with modiﬁcation of TLR pathways are
likely to be a logical therapeutic target for ALI.
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